Haematology


Our Team

Professor  Hang Quach | Director of Clinical Haematology | Director of Haematology Clinical Research
Haematologist 
Ph: (03) 9231 2030

A/Prof Merrole Cole-Sinclair | Director of Laboratory Haematology
Haematologist Ph: (03) 9231 3996

Dr Matthew Ku | Deputy Director of Haematology Clinical Research
Haematologist (Trials) Ph: (03) 9231 2030

A/Prof Ali Bazargan
Haematologist (Trials)

Dr Kritika Chaiwatanatorn
Haematologist    

Dr Anne Dykes
Haematologist

Dr Robin Filshie 
Haematologist

Dr Masa Lasica
Haematologist (Trials)

Dr Newton Lee        
Haematologist

Dr Slavisa Ninkovic
Haematologist

Dr Shuh Tan
Haematologist (Trials)

All our Haematologists can be contacted via St Vincent's Switchboard on Ph: (03) 9231 2211

Referral Information: Referrals are welcomed for patients with haematological disorders.
An MBS General Haematology clinic is also provided. 
Referral Forms and Guidelines


Haematology Clinical Trials

Haematology Clinical Research Unit - Current Open to recruitment trials as at April 2020 (listed below)

For more information please contact:
Lisa Demosthenous
Manager of Haematology Clinical Research Unit
lisa.demosthenous@svha.org.au
Ph: (03) 9231 3182

A/Prof Hang Quach, MBBS (Hons) SpecCertOC FRACP FRCPA MD
Director | Haematology Clinical Research | St Vincent’s Hospital
Interim Director | Clinical Haematology Service | St Vincent’s Hospital
hang.quach@svha.org.au

Dr Matthew Ku, MBBS SpecCertOC FRACP FRCPA PhD
Deputy Director of Haematology Clinical Research | St Vincent’s Hospital
Haematologist & Lymphoma Lead | St Vincent’s Hospital
matthew.ku@svha.org.au

Multiple Myeloma

Smoldering

Ithaca (SMM)

Phase 3 randomized, open label, multicenter study of Isatuximab in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma

Plan to open 30Jun2020

Newly Diagnosed

GSK2857916 DREAMM 9 (ND MM)

A Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Administered in Combination with Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone Alone in Participants with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplantation

Open to recruitment

IRiL (ND MM)

A prospective Phase II study of Isatuximab Rescue for Inadequate response to Lenalidomide and Dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma

Open to recruitment

MM21 (ND MM)

A multicentre, single arm, study of Daratumumab-Lenalidomide-dexamethasone (DRd) for newly diagnosed transplant eligible multiple myeloma patients who fail Bortezomib-based induction therapy.

Open to recruitment

Relapsed Refractory

AbbVie M15-654 (R/R MM)

A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma

Open to recruitment

Genentech GO41582 (R/R MM)

An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics of Escalating Doses of RO7297089 In Patients With Relapsed or Refractory Multiple Myeloma

Plan to open 30Jun2020

GSK2857916 DREAMM 3 (R/R MM)

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma

Open to recruitment

GSK2857916 DREAMM 5 (R/R MM)

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) in Combination with Anti- Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma

Open to recruitment

GSK207497 DREAMM 6 (R/R MM)

A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Treatment A), or Bortezomib Plus Dexamethasone (Treatment B) in Participants with Relapsed / Refractory Multiple Myeloma

Open to recruitment

TCD15484 Sub-Cut Isatuximab (R/R MM)

A multi-center, open-label, Phase 1b study to assess the pharmacokinetics, safety, and efficacy of subcutaneous and intravenous Isatuximab (SAR650984) in combination with Pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma

Open to recruitment

Chronic Lymphocytic Leukaemia & Lymphomas

Treatment Naïve

ALLG HD10 (TN HL)

Treatment optimization trial in the first-line treatment of advanced stage Hodgkin Lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD

Open to Recruitment

BGB3111_304 (TN CLL)

An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma

Open to recruitment

BGB-3111-306 Mangrove (TN MCL)

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Open to recruitment

PCYC1143 (TN MCL)

Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma

Open to recruitment

Treatment Naïve &

Relapsed Refractory

Assure (TN CLL, RR CLL)

A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic leukaemia

Open to Recruitment

TG-1701-110 (R/R CLL, WM, NHL, TN CLL, WM, MCL)

A Phase 1 Pharmacokinetic and Pharmacodynamics Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients with B-Cell Malignancies

Open to recruitment

Relapsed Refractory

Amgen 20140286 - Subcut Blinatumomab (R/R NHL)

A Phase 1b Open-label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma

Open to recruitment

Ascentage APG-2575-001 (R/R CLL, WM, DLBCL, AML, NHL, MCL)

A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2575 in Patients with hematologic malignancies

Open to recruitment

BGB-3111-305 Alpine (R/R CLL)

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic leukaemia or Small Lymphocytic Lymphoma

Open to recruitment

BGB-3111-LTE1 (R/R DLBCL, FL, CLL, SLL, MCL)

An Open-label, Multi-center, Long-term Extension

Study of Zanubrutinib (BGB-3111) in Patients with B Cell

Malignancies

Open to recruitment

BGB-A317-210 TIRHOL (R/R cHL)

A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Open to recruitment

Genentech GO29781 (R/R DLBCL, FL, MZL, NHL, RT, SLL, MCL)

An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Dose of BTCT4465A in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic leukaemia

Open to recruitment

GENMAB GCT3013-01 (R/R DLBCL and FL)

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma

Plan to open 30Jun2020

MERCK (MK-4280-003) (R/R HL, DLBCL, NHL)

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies

Open to recruitment

Roche GO41943 (R/R DLBCL)

A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of RO7082859 or Mosunetuzumab (RO7030816) in Combination with Gemcitabine plus Oxaliplatin in patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Open to recruitment

Acute Myeloid Leukaemia & Myelodysplastic Syndrome

Treatment Naïve

Culminate (TN AML)

A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukaemia who are not Candidates for Intensive Chemotherapy

Open to Recruitment

Registries / Other

Myeloma 1000 Registry

The Myeloma 1000 Project

Open to recruitment

MRDR Registry

Myeloma & Related Diseases Registry

Open to recruitment

NBCR

Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (previously known as AMLM18)

Open to recruitment

Carfilzomib Retrospective 20170766

Real-world Evidence of the Use of Carfilzomib Among Patients With Relapsed/Refractory Multiple Myeloma in Asia Pacific

Open to recruitment

Bleeding Disorders

TREATT

TREATT Trial to Evaluate Tranexamic acid therapy in Thrombocytopenia. A double blind randomized controlled trial evaluating the safety and efficacy of Tranexamic acid in patients with hematological malignancies with severe thrombocytopenia.


Myeloma Patients

Leukaemia Foundation-Myeloma, A guide for patients and families


Downloads


Leave a Message

Clinic Times

  • Thursday 9.30am

Contact Us

Patient Enquiries:

Tel: (03) 9231 3475

GP Enquiries:

Tel: (03) 9231 2898
Monday to Thursday: 8:30am to 4:30pm
Friday: 8:30am to 4:00pm, or please leave a message.

Fax referrals: (03) 9231 3489

Case Coordinator Nurse:

(03) 9231 3431

Referral Officer:

(03) 9231 3419


Health Pathways

HealthPathways Melbourne is an online portal designed to be used by general practice at the point of care to guide best practice assessment, management and referral of common clinical conditions.

 

Please Note:
This is a public outpatient service. All patients need to be referred to us by a GP. Please see your GP if you believe you would benefit from a referral to this clinic. Many doctors have private consulting suites as well as working in the public hospital system. This is entirely separate from St Vincent’s and our staff do not have any information about the private consulting practices of doctors.

 

Mandatory field(s) marked with *